Burkholderia pseudomallei: Difference between revisions

From IDWiki
Burkholderia pseudomallei
No edit summary
()
Line 3: Line 3:
 
* [[Has oxidase test::Oxidase-positive]], [[Has indole test::indole-negative]] [[Has Gram stain::Gram-negative]] [[Has cell shape::bacillus]] with "'''safety pin'''" appearance
 
* [[Has oxidase test::Oxidase-positive]], [[Has indole test::indole-negative]] [[Has Gram stain::Gram-negative]] [[Has cell shape::bacillus]] with "'''safety pin'''" appearance
 
* [[Has hemolysis pattern::Non-hemolytic]]
 
* [[Has hemolysis pattern::Non-hemolytic]]
  +
* Colonies are dry and wrinkly
   
 
=== Epidemiology ===
 
=== Epidemiology ===

Revision as of 11:50, 9 November 2019

Background

Microbiology

Epidemiology

  • Humans and animals
  • Important cause of death in SE Asia and northern Australia
    • Up to 80% seroprevalence in Thailand, mostly asymptomatic
    • Sporadic cases elsewhere
  • May have latent disease with reactivation much later
  • Acquired by percutaneous inoculation, inhalation (esp. lab workers), and ingestion
  • Risk factors for clinical disease
    • Diabetes
    • Heavy alcohol use
    • Chronic lung disease
    • Chronic kidney disease
    • Treatment with glucocorticoids
    • Cancer
    • Thalassemia

Clinical Presentation

  • Incubation period 9 days (range 1 to 21 days)
  • Presentations can vary from asymptomatic, skin ulcers, abscesses, latent infection, chronic pneumonia (similar to TB), or fulminant shock
    • Pneumonia (50%)
    • GU infection (15%)
    • Skin (15%)
    • Primary bacteremia (10%)
    • Septic arthritis/OM (3-5%)
    • Neuro (3-5%)
  • About 20% of clinical cases with develop septic shock

Diagnosis

  • Culture
    • Blood, throat, and urine cultures from all patients with suspected melioidosis
    • Grows on blood agar, MacConkey, etc. (i.e. not a fastidious organism)
    • Can use selective colistin or polymyxin B
    • On sheep blood agar, grows as small, smooth, cream-coloured colony with metallic sheen
    • May develop a dry and wrinkled appearance after 1 to 2 days of incubation
  • MALDI-ToF is not reliable for identifying it
  • Other methods
    • PCR
    • Immunofluorescence and latex agglutination
    • Serology (acute/convalescent)
  • Management

    • Intrinsic resistance to many antibiotics, especially using efflux pumps
    • Ceftazidime
    • Amoxicillin-clavulanic acid
    • TMP-SMX

    Biosafety

    • Lab workers can have aerosol exposure
    • May need prophylaxis in high-risk patients
      • Septra or doxy or amox/clav
  • Monitor with serology at baseline, weeks 1 2 4 and 6 post-exposure
    • Needs to be sent to CDC via NML
  • References

    1. ^  Bart J. Currie, Linda Ward, Allen C. Cheng. David Joseph Diemert. The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study. PLoS Neglected Tropical Diseases. 2010;4(11):e900. doi:10.1371/journal.pntd.0000900.
    2. ^  E. M. Meumann, A. C. Cheng, L. Ward, B. J. Currie. Clinical Features and Epidemiology of Melioidosis Pneumonia: Results From a 21-Year Study and Review of the Literature. Clinical Infectious Diseases. 2011;54(3):362-369. doi:10.1093/cid/cir808.